ABSTRACT: Our previous studies using puromycin aminonucleoside (PAN) established that podocyte damage leads to glomerular growth arrest during development and glomerulosclerosis later in life. This study examined the potential benefit of maintaining podocyte-derived VEGF in podocyte defense and survival after PAN injury using conditional transgenic podocytes and mice, in which human VEGF-A (hVEGF) transgene expression is controlled by tetracycline responsive element (TRE) promoter and reverse tetracycline transactivator (rtTA) in podocytes. In vitro experiments used primary cultured podocytes harvested from mice carrying podocinrtTA and TRE-hVEGF transgenes, in which hVEGF can be induced selectively. Induction of VEGF in PAN-exposed podocytes resulted in preservation of intrinsic VEGF, ␣-actinin-4 and synaptopodin, antiapoptotic marker Bcl-xL/Bax, as well as attenuation in apoptotic marker cleaved/total caspase-3. In vivo, compared with genotype controls, PAN-sensitive neonatal mice with physiologically relevant levels of podocyte-derived VEGF showed significantly larger glomeruli. Furthermore, PAN-induced up-regulation of desmin, downregulation of synaptopodin and nephrin, and disruption of glomerular morphology were significantly attenuated in VEGF-induced transgenic mice. Our data indicate that podocyte-derived VEGF provides self-preservation functions, which can rescue the cell after injury and preempt subsequent deterioration of the glomerulus in developing mice. (Pediatr Res 70: 83-89, 2011) A nimal models and clinical studies indicate that podocyte damage is a key step in progression of glomerular injury to glomerular sclerosis (1-3). Although podocyte damage involves oxidative stress, mechanical overstretch, and deficiency of slit diaphragm proteins and/or toxins, our understanding of the intrinsic protective mechanisms for podocyte preservation and repair associated with injury remains largely unknown.
A nimal models and clinical studies indicate that podocyte damage is a key step in progression of glomerular injury to glomerular sclerosis (1) (2) (3) . Although podocyte damage involves oxidative stress, mechanical overstretch, and deficiency of slit diaphragm proteins and/or toxins, our understanding of the intrinsic protective mechanisms for podocyte preservation and repair associated with injury remains largely unknown.
Vascular endothelial growth factor-A (VEGF-A) is an angiogenic and survival factor for endothelial cells (4, 5) , primarily expressed in glomerular podocytes (6) . Tight regulation of podocyte-derived VEGF is required for structural integrity of the glomerular endothelium (7, 8) . VEGF downregulation prevails in animal models (9 -11) and human diseases (12) (13) (14) where podocyte damage is thought to be intermediary in disease progression that culminates in glomerular injury and glomerulosclerosis (15) (16) (17) (18) . Supplementation of exogenous VEGF has been shown to attenuate glomerular lesions in remnant kidneys (9) . Recently, we showed that damage in a portion of the podocyte population causes damage in the remaining podocytes, creating an autonomous vicious cycle that promotes progressive damage and loss of podocytes (19) . We speculate that podocyte-derived VEGF functions as its own pivotal protective and survival factor after injury and have directly tested this hypothesis by enhancing podocyte VEGF that would otherwise be down-regulated upon exposure to insult. For this purpose, we studied puromycin aminonucleoside (PAN), a recognized podocyte toxin (20) . Our previous study found that adult mice are resistant to PAN injury while PAN-injured podocytes cause underdeveloped glomeruli in neonatal mice (21) . In this study, by using PAN-injured primary mouse podocytes and neonatal mice ( Fig. 1) , we demonstrated an autocrine podocyte survival effect of VEGF.
METHODS

Animals.
Conditional transgenic mice are generated, in which human VEGF (hVEGF) transgene expression is controlled by tetracycline responsive element (TRE) promoter and reverse tetracycline transactivator (rtTA) in podocytes upon presence of tetracycline derivative, doxycycline (Dox). Mice double-transgenic for podocin-rtTA and TRE-hVEGF (Tg) (22, 23) were obtained from heterozygous mating. WT or podocin-rtTA single transgenic littermates served as genotype control (Ctrl). Both lines were backcrossed to C57BL6 (Jackson Laboratory, Bar Harbor, ME) for more than 15 generations. Animal protocols were approved by Vanderbilt University Medical Center Institutional Animal Care and Use Committee in accordance with National Institutes of Health guidelines.
Isolation of glomeruli and podocyte culture. Glomeruli were isolated from 5-to 9-wk-old Tg and Ctrl mice using a modified methods of iron beads perfusion (Invitrogen, Carlsbad, CA), collagenase A dissociation (Roche Applied Science, Germany), and sieving (BD Falcon, Bedford, MA) (24, 25) , yielding glomerular purity Ͼ97% used in primary podocyte culture or ELISA. Podocytes (P0) outgrowing isolated glomeruli were identified by immunostainings for Wilms' tumor 1 (WT1; Santa Cruz Biotechnology, Santa Cruz, CA), nephrin (Progen, Germany) and synaptopodin (Progen). Only passage 3 (P3) podocytes were used in the in vitro studies.
To study effects of supplementing podocytes with recombinant human VEGF165 (rhVEGF; R&D Systems, Minneapolis, MN), P3 podocytes were treated with low-serum (2.5%) podocyte-conditioned medium and then with normal podocyte-conditioned medium containing rhVEGF (10 ng/mL), PAN (100 g/mL; Sigma Chemical Co.-Aldrich, St. Louis, MO), rhVEGF plus PAN, or PBS control for 48 h.
As our preliminary experiments showed slightly increased expression of cytoskeletal proteins in cultured podocytes with Dox treatment, to study the protective role of podocyte-derived VEGF against PAN-induced injury, paired Tg and Ctrl podocytes were both treated with Dox (1 g/mL; Sigma Chemical Co.-Aldrich) with or without PAN for 48 h.
PAN-induced podocyte injury in maturing mice. To induce hVEGF transgene expression, podocin-rtTA and TRE-hVEGF neonatal mice were treated with Dox (2 mg/mL in drinking water containing 1% sucrose) through the nursing dam starting on the day of delivery. PAN (50 g/g body weight, IP) or normal saline was injected 1 d after birth. Blood and urine were collected and kidneys harvested at 3 wk.
ELISA, Western blot analysis, and quantitative RT-PCR. Albuminuria was determined by urinary albumin to creatinine ratio (Exocell, Philadelphia, PA). Human or mouse-specific VEGF and soluble VEGF receptor 1, also known as soluble fms-like tyrosine kinase 1 (sFlt1), were measured by ELISA (R&D). Protein expression was assessed by Western blotting normalized to ␤-actin and synaptopodin mRNA by quantitative RT-PCR normalized to 18s rRNA (26) .
Immunocytochemistry and immunohistochemistry. Cells grown on slides were fixed in acetone, incubated with anti-synaptopodin, anti-WT1 (Santa Cruz), or anti-nephrin, followed by appropriate fluorescent secondary antibody. For F-actin staining of cultured podocytes, Alexa Fluor 546-labeled phalloidin (Invitrogen) was used. For immunohistochemistry, standard ABC method (Vector Labs, Burlingame, CA) was applied on paraffin-embedded kidney sections using anti-desmin (Abcam, UK), anti-nephrin, anti-WT1, anti-human VEGF (R&D), anti-human/mouse VEGF (Zymed, San Francisco, CA), or anti-mouse VEGF (Sigma Chemical Co.).
Glomerular morphometry. On each paraffin-embedded kidney section stained with WT1, Ͼ30 glomeruli were analyzed by ImageJ software (National Institutes of Health) and assessed for glomerular volume (V glom ), and density and number of WT1-positive podocytes by stereologic morphometrics (27) (28) (29) . Glomerular epithelial injury shown by desmin staining was graded on a 0 -4 scale, which represents the positive area involving 0%, 1-25%, 26 -50%, 51-75%, or Ͼ75% of the glomerular epithelium. For nephrinstained sections, all superficial glomeruli were analyzed by AxioVision software and percentage of positive area in the glomerulus averaged for each mouse. Measurements were validated separately by laboratory staff without knowledge of the groups.
Statistical analysis. Data were expressed as mean Ϯ SEM. Mann-Whitney U tests were used for between-group comparisons and Wilcoxon signed-rank tests for paired comparisons. All statistical tests were two-sided, and significance was defined as p Ͻ 0.05. Statistical analysis was performed using SPSS.
RESULTS
Effects of exogenous VEGF and PAN on podocyte VEGF (in vitro)
. Primary cultured mouse podocytes from WT adult mice were exposed to PAN or vehicle, and/or rhVEGF for 48 h. The supernatant concentration of hVEGF was 1 ng/mL, a level that was 3.79 Ϯ 0.12 fold of mouse VEGF-A (mVEGF). Furthermore, mVEGF levels in the supernatant or cell lysates were unaffected by supplementation with rhVEGF ( Table 1 ), suggesting that rhVEGF supplementation does not affect endogenous mVEGF. PAN significantly decreased podocyte mVEGF and significantly reduced hVEGF in lysates of cells treated with rhVEGF (Table 1 ). These results indicate that injured podocytes have reduced capacity to produce en- dogenous VEGF and have an impaired ability to interact with and/or take up supplemental VEGF. PAN significantly reduced expression of the podocyte cytoskeleton protein ␣-actinin-4 and increased expression of the apoptosis marker total caspase 3 and Bax. Supplementation of rhVEGF significantly attenuated these injury-related changes (Fig. 2) .
Effects of podocyte-derived VEGF on PAN-injured podocytes (in vitro). To study whether enhanced intrinsic podocyte-derived VEGF protects against injury, mouse podocytes double-transgenic for podocin-rtTA and TRE-hVEGF were exposed to PAN. Induction of hVEGF-A transgene was achieved by Dox. Induced hVEGF was detected in the supernatant of Tg podocytes as early as 1 h after Dox and was sustained. By contrast, hVEGF was not detected in Doxtreated WT or podocin-rtTA single transgenic podocytes (Ctrl podocytes). Intrinsic mVEGF expression and secretion were not significantly changed by induced expression of podocytederived hVEGF in Tg podocytes compared with Ctrl podo- cytes. The total human and mouse VEGF levels were some 6.5-fold higher in Tg podocyte lysate and 5.0-fold in Tg supernatant than the Ctrl. PAN significantly down-regulated expression of mVEGF in Tg and Ctrl podocytes and hVEGF in Dox-treated Tg podocytes. However, Dox-treated Tg podocytes with induced podocyte-derived VEGF significantly ameliorated reduction in mVEGF (Table 2) . Moreover, even 48 h after Dox, mVEGF levels in cell lysates and supernatants and hVEGF levels in supernatants were comparable between WT podocytes supplemented with rhVEGF and Dox-treated Tg podocytes with induced hVEGF (Tables 1 and 2) . PAN-exposed cultured podocytes showed retracted processes, disrupted and reduced cytoskeleton protein F-actin (Fig. 3A) , as well as down-regulated slit diaphragm protein synaptopodin, tight junction protein ZO-1, and cytoskeleton protein ␣-actinin-4 and ␣-tubulin. Tg podocytes with elevated podocyte VEGF had significantly ameliorated all these changes (Fig. 3B) . PAN also significantly increased apoptosis marker cleaved and total caspase 3, and tended to increase proapoptotic Bax and decrease antiapoptotic Bcl-xL in Ctrl podocytes. Tg podocytes with elevated podocyte VEGF had significantly preserved ratios of Bcl-xL/Bax and cleaved/totalcaspase 3 (Fig. 3B) .
Western blot analysis showed significantly up-regulated expression of VEGF receptor 1, also known as fms-like tyrosine kinase 1 (Flt1), in Tg podocytes with elevated podocyte VEGF but down-regulated in PAN-exposed podocytes. Induction of hVEGF expression significantly attenuated the change in Flt1 expression caused by PAN (Ctrl, 1.00 Ϯ 0.04; Tg, 2.08 Ϯ 0.07; Ctrl ϩ PAN, 0.59 Ϯ 0.08; Tg ϩ PAN, 0.94 Ϯ 0.11 fold change; all p Ͻ 0.05 for Tg versus Ctrl, Ctrl ϩ PAN versus Ctrl, and Tg ϩ PAN versus Ctrl ϩ PAN).
VEGF in podocin-rtTA/TRE-hVEGF double-transgenic mouse kidneys (in vivo).
To determine the transgene expression in vivo, immunostaining and ELISA for humanspecific VEGF were assessed. Human VEGF staining on kidney sections from adult mice treated with Dox for 1-4 wk showed positive transgene expression primarily in glomerular podocytes. Increased expression of podocyte hVEGF in Tg mice did not affect the level of intrinsic mVEGF (Fig. 4) , with an average of 1076.6 Ϯ 257.3 pg/mg protein in Ctrl glomeruli versus 1153.6 Ϯ 278.8 pg/mg protein in Tg glomeruli measured by ELISA (each n ϭ 3, p Ͼ 0.05). Quantitation of VEGF expression in isolated glomeruli showed that the amount of hVEGF was some 4-fold of mVEGF (Table 3 ). 
Effects of induction in podocyte VEGF on PAN podocyte injury (in vivo)
. hVEGF expression was observed in kidneys of 3-wk-old Dox-treated mice (Table 4) , localizing in podocytes (Fig. 5) of Tg but not Ctrl pups. Compared with the Ctrl, Dox-treated Tg mice with induced podocyte VEGF had larger glomeruli (Figs. 5 and 6A ), greater nephrin-positive glomerular areas (Table 5 ; Fig. 5 ), and increased synaptopodin mRNA (Fig. 6B) . Histological assessment revealed no structural damage in the glomerulus by induced podocyte VEGF (8) . These findings were supported by transmission electron microscopy, which also showed no appreciable differences in podocyte foot processes, glomerular basement membrane, and endothelial fenestrae between Ctrl and Tg mice (Fig. 5) .
PAN significantly reduced hVEGF expression in kidney homogenate of Tg pups (Table 4) . PAN also lessened renal synaptopodin mRNA expression in both Ctrl and Tg mice. These changes were significantly alleviated by induction of podocyte VEGF in Tg mice (Fig. 6) . Glomerular increase in desmin and decrease in nephrin induced by PAN were attenuated by enhanced expression of podocyte VEGF (Table 5 ; Fig. 5 ). Glomeruli of PAN-exposed Ctrl mice tended to have smaller glomerular volume (Table 5 ; p ϭ 0.094) with simpler branching of capillaries and higher podocyte density (Table 5 ; p ϭ 0.064) than non-PAN-treated Ctrl. Pairing Tg and Ctrl mice from the same litter according to the body weight revealed that induced expression of podocyte-derived VEGF increased glomerular volume in both PAN-exposed and non-PAN-exposed mice and decreased podocyte density in PANexposed mice (Fig. 6A) 
DISCUSSION
Using in vitro and in vivo transgenic models of inducible podocyte-specific VEGF, we demonstrate a protective effect of intrinsic VEGF against podocyte injury and suggest that podocyte-derived VEGF has a self-preserving autocrine function. Our data also indicate that augmentation of intrinsic podocyte VEGF within the physiological range can abort deterioration of glomerular development prompted by podocyte injury.
In our study, the podocyte-derived VEGF was increased by a maximum 6-fold of the intrinsic mVEGF in cultured podocytes (Table 2 ) and 4-fold in isolated glomeruli from Tg mice (Table 3 ). This level of increase parallels that observed in studies with hypoxia which induced 3-to 7-fold increase in VEGF-A expression or secretion in cultured cells (31) (32) (33) (34) . In vivo, VEGF was found 5-to 10-fold higher after hypoxia in the retina (35) , in the cornea with neovascularization (36) , and in tumor tissues (37) . Thus, data of our study indicated that the magnitude of increase in podocyte VEGF in the Tg mice was in the physiological rather than pharmacological range. Notably, this physiological level of VEGF induction did not result in proteinuria, glomerular endothelial injury, or glomerulosclerosis (8, 30) . Moreover, both ELISA measurement of cultured podocytes and isolated glomeruli indicated that the supplemental hVEGF transgene expression does not affect the level of intrinsic mVEGF. PAN has been shown to cause derangement and downregulation of cytoskeletal proteins as well as increased apoptosis in cultured podocytes (20, 38) , and podocyte foot process effacement and altered expression/localization of slit diaphragm proteins in vivo (38, 39) . In our study on primary podocytes, these changes were found associated with a significant decrease in cellular VEGF after PAN injury. The level of recombinant VEGF was also greatly reduced compared with podocytes without PAN injury. Therefore, PAN injury compromises podocyte survival by down-regulating intrinsic VEGF expression and/or reducing the cell's capability to use VEGF from adjacent podocytes. It is not known whether the turnover of VEGF is changed in diseased podocytes and whether higher dose of rhVEGF exerts greater protective effects. Given that the nature of podocyte deterioration follows an autonomous vicious cycle, our data suggest that supplementation of intrinsic VEGF protects podocytes by disrupting this injurious cycle (19) .
Previous studies in glomerular injury models (40, 41) suggested an antagonistic effect of soluble VEGF receptor 1 (sFlt1) on podocyte preservation, while decreased Flt1 expression has been linked to increased apoptosis (42, 43) . The sFlt1 levels in cultured podocyte supernatant in the current study were not significantly different after PAN and/or induction of VEGF expression. However, the Flt1 expression was decreased by PAN and increased in podocytes with induced hVEGF with or without PAN. Thus, the preserved Flt1 expression in PAN-injured podocytes may mediate the autocrine protective effects of VEGF against podocyte injury. Although VEGF receptor 2 (VEGFR-2) is regarded as functional receptor of VEGF, our study did not find convincing changes in its phosphorylation or expression in cultured podocytes (data not shown), which is consistent with a most recent finding that autocrine effects of podocyte VEGF may not actively involve VEGFR-2 (44) .
In vivo, mouse podocytes are sensitive to PAN only during the developmental stage (21) . Our previous study showed transient effacement of podocyte foot processes without proteinuria in neonatal mice after PAN injection (21) . The injured podocytes cause abnormal development of glomerular capillaries with simpler branching and reduced glomerular endothelial volume, changes that are more prominent in superficial than deep glomeruli (21) . In developing mice, we detected a significantly reduced expression of podocyte-specific synaptopodin and nephrin as well as an increase in desmin after PAN injury while no change in mVEGF likely due to contribution from its nonpodocyte sources. Enhanced expression of podocyte-derived VEGF not only significantly preserved synaptopodin and nephrin expression but also dampened upregulated desmin after PAN. These data indicate a selfprotective role of podocyte VEGF against injury and propagation of injury in vivo. Previous studies have shown that glomerular development is influenced by podocytederived VEGF (8, 45 ). In the current study, enhanced podocyte-derived VEGF caused larger glomerular volume in normally developing uninjured mice, whereas supplementing podocyte VEGF preserved glomerular growth deteriorated by PAN injury. The effects of enhanced podocyte VEGF on glomerular development also suggest a proangiogenic form of hVEGF rather than antiangiogenic splice variants (46) , and a paracrine effect of VEGF on endothelial cells in developing glomeruli (44) . The nonsignificant changes in podocyte density or number between the normal mice with and without enhanced podocyte VEGF, and the restored podocyte density in PAN-injured mice with enhanced podocyte VEGF, together with increased synaptopodin and nephrin expression, indicate that the enhanced expression of podocyte VEGF may be conducive for podocyte adaptation that occurs in parallel with enlargement of the glomerular vasculature under pathophysiological conditions.
In summary, our studies confirm an autocrine survival effect of VEGF in podocytes in vitro (47) (48) (49) and demonstrate protective roles of enhanced intrinsic VEGF against podocyte injury and in preservation of normal glomerular development in vivo.
